organization · Reporting owner
Lineage Cell Therapeutics, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Insight Molecular Diagnostics Inc.
Report date January 02, 2020 · Filed January 06, 2020
Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 6,041,154 |
Reported balance
After 2020-01-02 transaction · row 1
1 source rowRow 1 · 2020-01-02 · Sale · Disposed 2,383,090 · Balance 6,041,154 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2020 Filed Jan 6, 2020 22:00 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock, no par value | 2,383,090 | $2.16 | $5,137,942.04 |
DisclosureSEC source: 0001493152-20-000240 · ownership.xml · nonDerivative · entry 1 Lineage Cell Therapeutics, Inc. · CIK 0000876343 · Previous 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041,154 Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 21:20 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock, no par value | 4,000,000 | $1.66 | $6,640,000.00 |
DisclosureSEC source: 0001493152-19-014109 · ownership.xml · nonDerivative · entry 1 Lineage Cell Therapeutics, Inc. · CIK 0000876343 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,424,244 Read SEC document |
| July 05, 2019 Filed Jul 5, 2019 20:32 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock, no par value | 2,250,000 | $2.00 | $4,500,000.00 |
DisclosureSEC source: 0001209191-19-041335 · doc4.xml · nonDerivative · entry 1 BIOTIME INC · CIK 0000876343 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,424,244 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.